DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo

GlaxoSmithKline (NYSE: GSK)

company name or ticker
Company Photos
(Click to zoom)

What Pharma/Biotech Investors Need To Know About Adaptive Trials

Investors are terrified ... and they're overreacting

Sunshine Heart - A Speculative Biotech Play For Substantial Short-Term Gains

Stocks Bring High Dividend Yields to HOTCHKIS & WILEY

Innoviva: What Happens When Generic Advair Hits The Market?

5 Reasons Why GlaxoSmithKline Shareholders Should Be Excited About the Future

While presenting at the J.P. Morgan Healthcare Conference on Tuesday, CEO Andrew Witty hit on five key points that should get investors excited about GlaxoSmithKline's long-term potential.

Mylan N.V. Fires a Shot at GlaxoSmithKline

A generic version of Advair Diskus could be coming to the United States.

Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015

Clinical progress doesn't always translate into a higher share price.

Credit Rating Analysis: A Simple Way To Quantify And Compare Company Credit Ratings

PPH, NVS, GSK, NVO: Large Inflows Detected at ETF

See More Articles...